How does sharewise work?
Discuss
Discuss and share predictions for your favorite stocks in the forum. Let your opinion be heard
Show moreTop Buy/Sell (This Month)
| Security | Price | Target price |
|---|---|---|
| Microsoft Corp. | €415.15 | €501.09 |
| Amazon.com Inc. | €224.65 | €258.70 |
| Applied Materials Inc. | €465.95 | €496.17 |
| Security | Price | Target price |
|---|---|---|
| Clorox Co. | €90.76 | €91.19 |
| Western Union Co. | €6.20 | €7.01 |
| Socket Mobile Inc. | ? | - |
New Top predictions since last week
| Prediction | User | Perf. (%) |
|---|---|---|
| B Western Digital Corp. | RudolfL | 17.18% |
| B Semtech Corp. | Needham & Company LLC | 11.80% |
| B Super Micro Computer Inc. | Rosenblatt Securities | 9.98% |
| Prediction | User | Perf. (%) |
|---|---|---|
| S Capricor Therapeutics Inc | Bankster | -22.55% |
| S Capricor Therapeutics Inc | Vassago1 | -10.07% |
| S H&R Block Inc. | The Goldman Sachs Group, Inc. | -9.32% |
Portfolios of our members
Space X
When it comes to stocks, what is important for you?
Find stocks based on your criteria with our sharewise stock finder. All results are based on thousands of votes by our community
Pros and Cons of these stocks (New Predictions)
China Sxt Pharmaceuticals Inc.
WKN: A411L7 / Name: China Sxt Pharmaceuticals Inc. / Stock / ? /
Pros
Cons
EyePoint Pharmaceuticals Inc.
WKN: A2QJRU / Symbol: EYPT / Name: EyePoint Pharma / Stock / Biotechnology & Medical Research / Small Cap /
Pros
Cons
Try sharewise+ and get hundreds more matching stocks
Sign up for free!Tops & Flops S&P 500
| Security | Price | Change(%) (%) |
|---|---|---|
| Sandisk Corp. | €1,540.0 | 7.690% |
| Marvell Technology Inc. | €204.10 | 6.410% |
| Applied Materials Inc. | €465.95 | 6.300% |
| Lumentum Holdings Inc | €850.20 | 6.240% |
| Carnival Paired Ctf | €23.45 | 5.850% |
| Security | Price | Change(%) (%) |
|---|---|---|
| Constellation Brands Inc. | €113.00 | -6.220% |
| Charter Communications Inc. A | €125.72 | -5.710% |
| Coty Inc | €2.32 | -5.690% |
| KKR & Co. LP | €93.14 | -5.500% |
| Carvana Co. | €61.89 | -5.320% |
Courses
Key figures for stocks
sharewise Introduction
Predictions
Top News
Birkenstock Beats the Skeptics—But Not on EPS
Key Points
- Interested in Birkenstock Holding PLC? Here are five stocks we like better.
- Birkenstock beat revenue expectations and raised its full-year FY2026 guidance, though adjusted EPS came in
Oncocyte Eyes Faster, Less Invasive Heart Transplant Rejection Testing
Key Points
- Interested in Oncocyte Corp? Here are five stocks we like better.
- Insight Molecular Diagnostics is pursuing heart-transplant applications for its GraftAssureDx donor-derived cell-free
Fortinet Sees Surging Hardware, SASE Demand as AI and OT Security Fuel Growth
Key Points
- Interested in Fortinet, Inc.? Here are five stocks we like better.
- Demand accelerated across Fortinet’s business, with product revenue up 52% and customers purchasing larger
EyePoint’s DURAVYU Misses Primary Endpoint in Phase III Wet AMD Trial
Key Points
- Interested in Eyepoint Pharmaceuticals, Inc.? Here are five stocks we like better.
- EyePoint’s DURAVYU missed the primary endpoint in the Phase III LUGANO wet AMD trial, failing to
Erdene Resource Development Q2 Earnings Call Highlights
Key Points
- Interested in Erdene Resource Development Co.? Here are five stocks we like better.
- Bayan Khundii production improved: Second-quarter gold output rose 37% quarter over quarter to
Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?
QuidelOrtho Corporation QDEL is showing resilience in its core diagnostics businesses, but the investment case remains constrained by worsening visibility in China, uncertain respiratory demand and
Robinhood's July DATs Rise Y/Y: Is Its Expansion Strategy Working?
Robinhood Markets, Inc. HOOD reported strong growth in equity and options Daily Average Trades (DATs) in July 2026, underscoring continued momentum in its active-trader business. Equity DATs rose
QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?
QuidelOrtho Corporation QDEL has gained 31.7% in the past three months, but the rally now faces a mixed operating backdrop. Core diagnostics businesses are still growing, and cost actions are
Wells Fargo's NII Outlook: Can It Achieve the $50B Target in 2026?
Wells Fargo & Company WFC expects its net interest income (NII) to reach approximately $50 billion in 2026, up from $47.5 billion in 2025. The outlook reflects continued balance-sheet expansion
Jabil Rides on AI Data Center Boom: Is More Growth Ahead?
Jabil, Inc. JBL is benefiting from solid momentum in the AI infrastructure market. The company has developed a comprehensive portfolio spanning computing, storage, networking, optics, power and
News
NOK Rides on Strength of Network Infrastructure: Will the Gain Last?
Nokia Corporation NOK is benefiting from solid revenue growth in the Network Infrastructure segment. During the second quarter, net sales from Network Infrastructure totaled €2.04 billion ($2.37
SUNation Stock Dips Post Q2 Earnings, Revenues Decline Y/Y
Shares of SUNation Energy, Inc. SUNE have lost 0.8% since the company reported its earnings for the quarter ended June 30, 2026, against the S&P 500 Index’s 0.7% rise over the same period. Over the
CVD Stock Up Post Q2 Earnings Despite Revenue Fall, SDC Sale Lifts Cash
Shares of CVD Equipment Corporation CVV have gained 3.3% since the company reported its earnings for the quarter ended June 30, 2026, outperforming the S&P 500 Index’s 0.7% rise over the same
Can Boot Barn's Digital Strategy Maintain Its Growth Momentum?
Boot Barn Holdings, Inc. BOOT delivered strong e-commerce performance in the first quarter, with comparable e-commerce sales increasing 13.4%, driven by double-digit growth on bootbarn.com. The
Rigetti's Expanding Commercial Base Strengthens Growth Prospects
Rigetti Computing’s RGTI second-quarter 2026 results highlighted a potentially important shift in the quantum computing market, with commercial traction emerging alongside government and academic
Can Arhaus' Showroom Expansion Drive Its Next Phase of Growth?
Arhaus, Inc.’s ARHS showrooms remain a central element of the brand, serving as an important driver of awareness, engagement and conversion. Beyond showcasing products, the showrooms bring the brand
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
NeuroPace, Inc. NPCE has hit a regulatory delay in its bid to expand the RNS System into idiopathic generalized epilepsy, or IGE. The FDA’s July 2026 response pushes out a potential growth catalyst
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
NeuroPace, Inc. NPCE is showing better operating momentum as RNS System adoption expands and losses narrow. Second-quarter results supported the growth case, while a broader commercial reach and new
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?
NeuroPace, Inc. NPCE shares have declined 12.7% in the past three months even as the company’s core responsive neurostimulation, or RNS, franchise has continued to strengthen. The pullback leaves
Contest
Still running
Heibel Ticker
sharewise sagt: Stephan Heibel ist ein langähriger Unterstützer und Autor der Wunschanalyse. Er betreibt meiner Meinung nach einen der besten Börsenbriefe. Es gibt eine kostenlose und eine Premium Variante.
Kostenlos ausprobierensharewise
Du findest das sharewise Projekt spannend und möchtest es unterstützen?
Mit einer
sharewise+-Mitgliedschaft
unterstützt du uns finanziell und bekommst zusätzliche Funktionalitäten freigeschalten.
Leeway
Die Analyse-Plattform Leeway untersucht mit KI-unterstützten Algorithmen aussagekräftige Zusammenhänge am Aktienmarkt. Anhand von vielen Millionen Datenpunkten finden die Algorithmen die Kennzahlen und Bewegungen, die nachweisbare Auswirkungen haben und Vorteile schaffen.
Kostenlos ausprobierensharewise
Du findest das sharewise Projekt spannend und möchtest es unterstützen?
Mit einer
sharewise+-Mitgliedschaft
unterstützt du uns finanziell und bekommst zusätzliche Funktionalitäten freigeschalten.







